Boston Scientific upside scenario unlikely after data, says Wells Fargo

Wells Fargo says that while Boston Scientific’s (BSX) CHAMPION-AF trial met its endpoints, the data is unlikely to accelerate Watchman growth given a slightly higher ischemic stroke rate. Watchman left atrial appendage closure was non-inferior to novel oral anticoagulants on the primary efficacy endpoint, but was numerically worse driven by the rate of stroke being slightly worse for Watchman, the analyst tells investors in a research note. Wells views the CHAMPION-AF as “good, not great.” The upside scenario is now unlikely, says the firm, which tweaked Boston Scientific’s estimates lower but keeps an Overweight rating on the shares. The stock in early trading is down 6% to $65.18.